QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
Log in
NASDAQ:CRON

Cronos Group Competitors

$9.64
-0.67 (-6.50 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.37
Now: $9.64
$10.40
50-Day Range
$9.91
MA: $11.41
$15.55
52-Week Range
$4.00
Now: $9.64
$15.83
Volume6.76 million shs
Average Volume7.92 million shs
Market Capitalization$3.47 billion
P/E Ratio40.17
Dividend YieldN/A
Beta2.07

Competitors

Cronos Group (NASDAQ:CRON) Vs. CGC, APHA, TLRY, USNA, ACB, and SNDL

Should you be buying CRON stock or one of its competitors? Companies in the industry of "medicinals & botanicals" are considered alternatives and competitors to Cronos Group, including Canopy Growth (CGC), Aphria (APHA), Tilray (TLRY), USANA Health Sciences (USNA), Aurora Cannabis (ACB), and Sundial Growers (SNDL).

Canopy Growth (NASDAQ:CGC) and Cronos Group (NASDAQ:CRON) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, institutional ownership and profitability.

Volatility and Risk

Canopy Growth has a beta of 2.44, meaning that its stock price is 144% more volatile than the S&P 500. Comparatively, Cronos Group has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500.

Valuation and Earnings

This table compares Canopy Growth and Cronos Group's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canopy Growth$297.34 million39.20$-993,370,000.00$1.3223.49
Cronos Group$25.64 million135.45$1.17 billion$0.6714.39

Cronos Group has lower revenue, but higher earnings than Canopy Growth. Cronos Group is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Canopy Growth and Cronos Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Canopy Growth-312.84%-13.11%-9.66%
Cronos Group266.31%-1.61%-1.41%

Analyst Ratings

This is a summary of recent ratings for Canopy Growth and Cronos Group, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Canopy Growth510412.05
Cronos Group25202.00

Canopy Growth currently has a consensus price target of $38.5667, indicating a potential upside of 24.37%. Cronos Group has a consensus price target of $8.8333, indicating a potential downside of 8.37%. Given Canopy Growth's stronger consensus rating and higher possible upside, analysts clearly believe Canopy Growth is more favorable than Cronos Group.

Insider and Institutional Ownership

10.2% of Canopy Growth shares are held by institutional investors. Comparatively, 11.8% of Cronos Group shares are held by institutional investors. 0.3% of Canopy Growth shares are held by insiders. Comparatively, 7.9% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Cronos Group beats Canopy Growth on 8 of the 15 factors compared between the two stocks.

Cronos Group (NASDAQ:CRON) and Aphria (NASDAQ:APHA) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations for Cronos Group and Aphria, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cronos Group25202.00
Aphria03602.67

Cronos Group currently has a consensus target price of $8.8333, indicating a potential downside of 8.37%. Aphria has a consensus target price of $17.7857, indicating a potential upside of 6.44%. Given Aphria's stronger consensus rating and higher possible upside, analysts plainly believe Aphria is more favorable than Cronos Group.

Volatility and Risk

Cronos Group has a beta of 2.07, indicating that its share price is 107% more volatile than the S&P 500. Comparatively, Aphria has a beta of 2.67, indicating that its share price is 167% more volatile than the S&P 500.

Profitability

This table compares Cronos Group and Aphria's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cronos Group266.31%-1.61%-1.41%
Aphria-36.10%-2.30%-1.66%

Insider & Institutional Ownership

11.8% of Cronos Group shares are owned by institutional investors. Comparatively, 10.3% of Aphria shares are owned by institutional investors. 7.9% of Cronos Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Cronos Group and Aphria's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos Group$25.64 million135.45$1.17 billion$0.6714.39
Aphria$405.96 million13.04$-63,210,000.00($0.06)-278.50

Cronos Group has higher earnings, but lower revenue than Aphria. Aphria is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Summary

Cronos Group beats Aphria on 9 of the 14 factors compared between the two stocks.

Cronos Group (NASDAQ:CRON) and Tilray (NASDAQ:TLRY) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.

Insider and Institutional Ownership

11.8% of Cronos Group shares are held by institutional investors. Comparatively, 12.6% of Tilray shares are held by institutional investors. 7.9% of Cronos Group shares are held by company insiders. Comparatively, 16.8% of Tilray shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Cronos Group has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500. Comparatively, Tilray has a beta of 3.12, suggesting that its stock price is 212% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Cronos Group and Tilray, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cronos Group25202.00
Tilray210001.83

Cronos Group currently has a consensus price target of $8.8333, indicating a potential downside of 8.37%. Tilray has a consensus price target of $18.3078, indicating a potential downside of 19.17%. Given Cronos Group's stronger consensus rating and higher possible upside, research analysts clearly believe Cronos Group is more favorable than Tilray.

Profitability

This table compares Cronos Group and Tilray's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cronos Group266.31%-1.61%-1.41%
Tilray-242.60%-92.70%-20.70%

Valuation and Earnings

This table compares Cronos Group and Tilray's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos Group$25.64 million135.45$1.17 billion$0.6714.39
Tilray$166.98 million23.30$-321,170,000.00($1.69)-13.40

Cronos Group has higher earnings, but lower revenue than Tilray. Tilray is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Summary

Cronos Group beats Tilray on 10 of the 14 factors compared between the two stocks.

USANA Health Sciences (NYSE:USNA) and Cronos Group (NASDAQ:CRON) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.

Profitability

This table compares USANA Health Sciences and Cronos Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
USANA Health Sciences10.57%32.91%22.26%
Cronos Group266.31%-1.61%-1.41%

Insider & Institutional Ownership

54.1% of USANA Health Sciences shares are held by institutional investors. Comparatively, 11.8% of Cronos Group shares are held by institutional investors. 45.4% of USANA Health Sciences shares are held by insiders. Comparatively, 7.9% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk and Volatility

USANA Health Sciences has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, Cronos Group has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500.

Valuation and Earnings

This table compares USANA Health Sciences and Cronos Group's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
USANA Health Sciences$1.06 billion1.99$100.53 million$4.4122.71
Cronos Group$25.64 million135.45$1.17 billion$0.6714.39

Cronos Group has lower revenue, but higher earnings than USANA Health Sciences. Cronos Group is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for USANA Health Sciences and Cronos Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
USANA Health Sciences00203.00
Cronos Group25202.00

USANA Health Sciences presently has a consensus target price of $126.00, indicating a potential upside of 25.82%. Cronos Group has a consensus target price of $8.8333, indicating a potential downside of 8.37%. Given USANA Health Sciences' stronger consensus rating and higher probable upside, research analysts plainly believe USANA Health Sciences is more favorable than Cronos Group.

Summary

USANA Health Sciences beats Cronos Group on 8 of the 13 factors compared between the two stocks.

Aurora Cannabis (NYSE:ACB) and Cronos Group (NASDAQ:CRON) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Volatility & Risk

Aurora Cannabis has a beta of 3.44, indicating that its stock price is 244% more volatile than the S&P 500. Comparatively, Cronos Group has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500.

Profitability

This table compares Aurora Cannabis and Cronos Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aurora Cannabis-1,238.94%-16.32%-13.12%
Cronos Group266.31%-1.61%-1.41%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Aurora Cannabis and Cronos Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aurora Cannabis69001.60
Cronos Group25202.00

Aurora Cannabis presently has a consensus price target of $11.2445, indicating a potential upside of 14.51%. Cronos Group has a consensus price target of $8.8333, indicating a potential downside of 8.37%. Given Aurora Cannabis' higher possible upside, equities analysts plainly believe Aurora Cannabis is more favorable than Cronos Group.

Valuation and Earnings

This table compares Aurora Cannabis and Cronos Group's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora Cannabis$207.89 million9.32$-2,468,190,000.00($2.86)-3.43
Cronos Group$25.64 million135.45$1.17 billion$0.6714.39

Cronos Group has lower revenue, but higher earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

11.9% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 11.8% of Cronos Group shares are owned by institutional investors. 7.9% of Cronos Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Cronos Group beats Aurora Cannabis on 10 of the 14 factors compared between the two stocks.

Cronos Group (NASDAQ:CRON) and Sundial Growers (NASDAQ:SNDL) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Volatility and Risk

Cronos Group has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500. Comparatively, Sundial Growers has a beta of 7.01, meaning that its stock price is 601% more volatile than the S&P 500.

Profitability

This table compares Cronos Group and Sundial Growers' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cronos Group266.31%-1.61%-1.41%
Sundial Growers-415.89%-187.67%-72.67%

Analyst Ratings

This is a breakdown of recent ratings for Cronos Group and Sundial Growers, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cronos Group25202.00
Sundial Growers12001.67

Cronos Group presently has a consensus target price of $8.8333, indicating a potential downside of 8.37%. Sundial Growers has a consensus target price of $1.00, indicating a potential downside of 13.79%. Given Cronos Group's stronger consensus rating and higher probable upside, research analysts clearly believe Cronos Group is more favorable than Sundial Growers.

Valuation & Earnings

This table compares Cronos Group and Sundial Growers' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos Group$25.64 million135.45$1.17 billion$0.6714.39
Sundial Growers$75.86 million23.88$-204,570,000.00($3.17)-0.37

Cronos Group has higher earnings, but lower revenue than Sundial Growers. Sundial Growers is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

11.8% of Cronos Group shares are held by institutional investors. Comparatively, 3.3% of Sundial Growers shares are held by institutional investors. 7.9% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Cronos Group beats Sundial Growers on 12 of the 14 factors compared between the two stocks.

pixel
Ad True Market Insiders
Insider: How To Invest In Amazon, Facebook & More For 21X LESS
Millionaire investor and former Wall Street insider reveals why tech stocks are about to explode - plus how to buy all the major players with ONE trade at 21X less cost.

Cronos Group Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Canopy Growth logo
CGC
Canopy Growth
0.8$31.01-7.2%$11.65 billion$297.34 million-9.28Decrease in Short Interest
Aphria logo
APHA
Aphria
1.3$16.71-8.8%$5.29 billion$405.96 million-28.32
Tilray logo
TLRY
Tilray
1.0$22.65-11.7%$3.89 billion$166.98 million-4.99
USANA Health Sciences logo
USNA
USANA Health Sciences
2.0$100.14-0.3%$2.11 billion$1.06 billion18.54Insider Selling
Aurora Cannabis logo
ACB
Aurora Cannabis
1.3$9.82-6.5%$1.94 billion$207.89 million-0.40Decrease in Short Interest
Sundial Growers logo
SNDL
Sundial Growers
1.0$1.16-12.1%$1.81 billion$75.86 million-0.45Increase in Short Interest
Gap Up
HEXO logo
HEXO
HEXO
0.9$6.52-7.4%$796.50 million$60.46 million-1.34
ChromaDex logo
CDXC
ChromaDex
0.9$9.58-19.1%$591.93 million$46.29 million-25.21Upcoming Earnings
MediWound logo
MDWD
MediWound
1.4$5.19-6.6%$141.36 million$31.79 million-12.97Earnings Announcement
Analyst Report
Decrease in Short Interest
Analyst Revision
Natural Alternatives International logo
NAII
Natural Alternatives International
0.4$14.49-0.8%$92.13 million$118.88 million181.15Increase in Short Interest
Gap Down
HAPP
Happiness Biotech Group
0.6$1.85-5.4%$47.92 million$65.06 million0.00Gap Up
MTEX
Mannatech
1.1$18.34-1.0%$38.29 million$157.73 million5.64Dividend Announcement
News Coverage
HUGE
FSD Pharma
0.3$1.78-9.0%$34.11 million$190,000.00-0.40Increase in Short Interest
Gap Up
CYAN
Cyanotech
0.6$3.55-5.9%$21.64 million$31.90 million35.50High Trading Volume
Decrease in Short Interest
News Coverage
This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.